Kezar Life Sciences (KZR) News Today $6.38 -0.14 (-2.15%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Kezar Life Sciences price target lowered to $9 from $11 at Wells FargoDecember 19 at 1:36 PM | markets.businessinsider.comKezar Life Sciences updates shareholder rights agreementDecember 5, 2024 | investing.comHC Wainwright Issues Pessimistic Outlook for KZR EarningsKezar Life Sciences, Inc. (NASDAQ:KZR - Free Report) - Research analysts at HC Wainwright reduced their Q4 2024 earnings estimates for Kezar Life Sciences in a research note issued to investors on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($December 4, 2024 | marketbeat.comKezar Life Sciences (KZR) Receives a Hold from H.C. WainwrightDecember 2, 2024 | markets.businessinsider.comFY2024 Earnings Estimate for KZR Issued By William BlairKezar Life Sciences, Inc. (NASDAQ:KZR - Free Report) - Analysts at William Blair boosted their FY2024 earnings per share (EPS) estimates for Kezar Life Sciences in a research note issued on Wednesday, November 13th. William Blair analyst M. Phipps now forecasts that the company will post earningsNovember 18, 2024 | marketbeat.comKezar struck again with second FDA holdNovember 14, 2024 | msn.comWells Fargo & Company Issues Pessimistic Forecast for Kezar Life Sciences (NASDAQ:KZR) Stock PriceWells Fargo & Company reduced their price target on Kezar Life Sciences from $20.00 to $11.00 and set an "equal weight" rating on the stock in a report on Thursday.November 14, 2024 | marketbeat.comKezar Life Sciences' (KZR) "Market Perform" Rating Reaffirmed at William BlairWilliam Blair reiterated a "market perform" rating on shares of Kezar Life Sciences in a research note on Wednesday.November 13, 2024 | marketbeat.comKezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | finanznachrichten.deKezar Life Sciences (KZR) Receives a Buy from TD CowenNovember 13, 2024 | markets.businessinsider.comGlancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)November 5, 2024 | businesswire.comKezar Life Sciences Share Price (KZR.US)November 4, 2024 | lse.co.ukKezar Life Sciences (NASDAQ:KZR) Shares Gap Down - Here's What HappenedKezar Life Sciences (NASDAQ:KZR) Shares Gap Down - Here's WhyOctober 30, 2024 | marketbeat.comKezar Life Sciences trading halted, news pendingOctober 30, 2024 | markets.businessinsider.comKezar Life Sciences Stock Scheduled to Reverse Split on Wednesday, October 30th (NASDAQ:KZR)Kezar Life Sciences, Inc. (NASDAQ:KZR - Free Report)'s stock is going to reverse split on the morning of Wednesday, October 30th. The 1-10 reverse split was announced on Monday, October 28th. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, October 29th.October 28, 2024 | marketbeat.comKezar Life Sciences Announces 1-for-10 Reverse Stock SplitOctober 28, 2024 | finance.yahoo.comKezar Life Sciences Announces One-for-ten Reverse Stock SplitOctober 28, 2024 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for Kezar Life Sciences (KZR)October 19, 2024 | markets.businessinsider.comKezar Life Sciences discontinues lupus nephritis programme after fatalitiesOctober 19, 2024 | msn.comKezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights PlanOctober 17, 2024 | stockhouse.comKezar to discontinue mid-stage trial for lupus treatmentOctober 17, 2024 | msn.comKezar Life Rejects Proposal From Concentra; Board Adopts Limited Duration Stockholder Rights PlanOctober 17, 2024 | markets.businessinsider.comKezar stock falls 9% after board rejects Concentra takeover offerOctober 17, 2024 | msn.comPenny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis StudyOctober 17, 2024 | finance.yahoo.comKezar discontinues development of zetomipzomib for lupus nephritisOctober 17, 2024 | msn.comKezar Life Sciences, Inc. (NASDAQ:KZR) Sees Significant Growth in Short InterestKezar Life Sciences, Inc. (NASDAQ:KZR - Get Free Report) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 982,900 shares, an increase of 13.6% from the September 15th total of 865,600 shares. Based on an average trading volume of 834,500 shares, the days-to-cover ratio is presently 1.2 days.October 15, 2024 | marketbeat.comKezar Life Sciences (NASDAQ:KZR) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of Kezar Life Sciences in a research report on Monday.October 14, 2024 | marketbeat.comKezar Confirms Receipt of Unsolicited, Non-Binding Acquisition ProposalOctober 10, 2024 | finance.yahoo.comTANG CAPITAL MANAGEMENT LLC Acquires New Stake in Kezar Life Sciences IncOctober 10, 2024 | finance.yahoo.comFDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient DeathsOctober 7, 2024 | benzinga.comKezar Life Sciences' Zetomipzomib IND For Lupus Nephritis Placed On Clinical Hold By FDA; Stock DownOctober 5, 2024 | markets.businessinsider.comUS FDA puts Kezar Life Sciences' lupus treatment trial on hold after patient deathsOctober 5, 2024 | reuters.comUS FDA puts clinical hold on Kezar Life Sciences' lupus treatment trialOctober 4, 2024 | reuters.comKezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus NephritisOctober 4, 2024 | businesswire.comKezar Life Sciences maintains Buy stock rating despite trial pauseOctober 3, 2024 | uk.investing.comHC Wainwright & Co. Downgrades Kezar Life Sciences (KZR)October 3, 2024 | msn.comHC Wainwright Reaffirms Neutral Rating for Kezar Life Sciences (NASDAQ:KZR)HC Wainwright restated a "neutral" rating on shares of Kezar Life Sciences in a research report on Wednesday.October 2, 2024 | marketbeat.comMaintaining Hold on Kezar Life Sciences Amid Safety Concerns and Financial ValuationOctober 1, 2024 | markets.businessinsider.comTD Cowen Remains a Buy on Kezar Life Sciences (KZR)October 1, 2024 | markets.businessinsider.comKezar Life Sciences Halts Trial of Lupus-Nephritis Treatment After DeathsOctober 1, 2024 | marketwatch.comStonepine Capital Management LLC Makes New $630,000 Investment in Kezar Life Sciences, Inc. (NASDAQ:KZR)Stonepine Capital Management LLC purchased a new position in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 1,050,452 shares of the company's stock, valued at approOctober 1, 2024 | marketbeat.comKezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis PatientsSeptember 30, 2024 | finance.yahoo.comKezar Life Sciences halts mid-stage trial for lupus treatmentSeptember 30, 2024 | reuters.comKezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis PatientsSeptember 30, 2024 | businesswire.comKezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | finance.yahoo.comBuy Rating on Kezar Life Sciences Backed by Promising Zetomipzomib Clinical TrialsAugust 15, 2024 | markets.businessinsider.comKezar stalls solid tumour trial to focus on autoimmune disease candidateAugust 14, 2024 | finance.yahoo.comKezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor DrugAugust 14, 2024 | benzinga.comKezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | finanznachrichten.deKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)June 7, 2024 | businesswire.com Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. KZR Media Mentions By Week KZR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KZR News Sentiment▼-0.370.61▲Average Medical News Sentiment KZR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KZR Articles This Week▼21▲KZR Articles Average Week Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALEC News Today LYEL News Today CHRS News Today OGI News Today AMRN News Today GNFT News Today OPT News Today SLDB News Today KYTX News Today GOSS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KZR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
